Publications by authors named "N Yamashita"
Background: Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab have been established as the optimal systemic therapies for patients with early stage triple-negative breast cancer (TNBC); however, their efficacy and feasibility in the Japanese population remain unexplored.
Methods: This study included patients with early stage TNBC or low estrogen receptor (ER) positivity (1-9%) with human epidermal growth factor receptor type 2- (HER2-) negative breast cancer who received neoadjuvant pembrolizumab plus chemotherapy from October 2022 at Cancer Institute Hospital of Japanese Foundation for Cancer Research. Information regarding clinicopathological features, systemic therapy, treatment outcomes, and adverse events of patients who underwent surgery by February 2024 was retrospectively collected.
Article Synopsis
- Ivabradine is a new treatment for heart rate reduction in patients with reduced ejection fraction heart failure, and this study evaluates its cost-effectiveness in Japan.
- A Markov model was used to compare ivabradine plus standard therapy against standard therapy alone, focusing on Quality-Adjusted Life Years (QALY) for patients with resting heart rates ≥ 75 bpm and ≥ 70 bpm.
- The study found that ivabradine is likely cost-effective, with an incremental cost-effectiveness ratio of around JPY 2.46 million to JPY 2.56 million per QALY, making it a viable option for patients with chronic heart failure in Japan.
Article Synopsis
- The chapter explains how lattice light-sheet microscopy (LLSM) enables detailed tracking of microtubule growth during cell division, using a special protein marker for precision.
- It outlines statistical methods for analyzing the complex three-dimensional data collected from this imaging technology.
- The discussion also includes future possibilities for improving the analysis of large-scale image datasets in biological research.
Association Between Coagulation Fibrinolysis Markers and Severity in Patients with COVID-19.
Clin Appl Thromb Hemost
November 2024
Introduction: Thrombosis is a major complication of COVID-19. D-dimer (DD) is an important coagulation fibrinolysis marker in COVID-19 and has been extensively studied. However, very little is known about the role of other fibrinolysis markers, plasmin-plasmin inhibitor complex (PIC), and fibrin monomer complex (FMC) in COVID-19.
View Article and Find Full Text PDF